Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

PBYI

+ Watchlist+ Portfolio

Puma Biotechnology Inc

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$7.14
52-Week Range
$4.80 – $11.50
Market Cap
$373.26M
P/E (TTM)
15.70
EPS (TTM)
0.46
Dividend Yield
0.00%
Advanced Metrics
Price/Book
2.55
PEG Ratio
—
Return on Equity
18.20%
Return on Assets
8.05%
Gross Margin
73.59%
Operating Margin
11.27%
Profit Margin
10.28%
Current Ratio
3.03
Debt/Equity
0.03
Total Debt
$4.87M
Free Cash Flow
$37.68M
Revenue Growth
1.10%
Earnings Growth
-35.30%
Enterprise Value
$269.55M

Market Snapshot

About

Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of innovative products to enhance cancer care. The company markets NERLYNX (neratinib), an oral kinase inhibitor approved for the extended adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Puma also has a pipeline of drug candidates in clinical development for various oncology indications. The company was founded in 2010 and is headquartered in Los Angeles, California.